MD Anderson initiates Phase 1/2 entinostat-lapatinib ditosylate combination study in

[News]

Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announced that investigators at The University of Texas MD Anderson Cancer Center Department of Breast Medical Oncology have initiated a phase 1/2 study combining Syndax's lead product entinostat with lapatinib ditosylate (Tykerb) in patients with locally recurrent or distant relapsed metastatic breast cancer previously treated with trastuzumab (Herceptin).

More... (http://www.news-medical.net/news/20120409/MD-Anderson-initiates-Phase-12-entinostat-lapatinib-ditosylate-combination-study-in-metastatic-breast-cancer.aspx)